Double-barreled cell therapy aims to beat leukemia relapse
NCT ID NCT05470777
First seen May 28, 2026 · Last updated Jun 13, 2026 · Updated 2 times
Summary
This study tests a new treatment for B-cell acute lymphoblastic leukemia that combines two types of CAR-T cells (targeting CD22 and CD19) with a stem cell transplant using the patient's own cells. The goal is to lower the chance of the cancer coming back after treatment. 37 participants are being followed to see how long they live without the disease returning.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
Conditions
Explore the condition pages connected to this study.